At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 662 enrolled
Drug / intervention
Centanafadine SRdrug
Likely dose
Centanafadine SR 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Jul 30, 2018·Updated Oct 1, 2024
In Brief
A Phase 3 clinical trial evaluating Centanafadine SR for Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder. Completed, enrolled 662 participants across 1 site.
Detailed Summary
This study evaluated the long-term safety and tolerability of centanafadine sustained-release (SR) tablets, administered twice daily (BID) in the treatment of adults with attention deficit hyperactivity disorder (ADHD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartFeb 2019
Primary CompletionSep 2021
TodayJul 2026
First PostedJul 30, 2018
Enrollment StartFeb 14, 2019
Primary CompletionSep 7, 2021
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 7.9 years ago
Interventions
Centanafadine SRdrug
200mg, BID, oral tablets